Latest posts
-
StemSation International Announces Acquisition Plans
StemSation International is providing updates on corporate planning and direction for potential new acquisitions in the green energy space Plantation, Florida, September 27, 2023 – StemSation International (OTC: STSN), a South-Florida based company that has licensed technology for the production and distribution of flavored, canned oxygen products is announcing strategic acquisition planning for the upcoming
-
BioStem Technologies Takes on Diabetic Foot Ulcers with Innovative Wound Care Product
“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already
-
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje® in Diabetic Foot Ulcers
POMPANO BEACH, FLORIDA, September 26, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of
-
TransGlobal Assets Inc. (OTC: TMSH) Wholly Owned Subsidiary, Better Health Sciences Inc., Acquires the Assets of Synergy Health Services Inc.
Ann Arbor, Michigan, September 26, 2023 – TransGlobal Assets Inc. (OTC: TMSH) is pleased to announce that, pursuant to an Acquisition Agreement, its wholly owned subsidiary Better Health Sciences, Inc., has acquired 100% of the assets of Synergy Health Services Inc. Synergy Health Services Inc., is a multidisciplinary Wellness Centre that provides evidence-based natural health
-
RIGHT ON BRANDS – CORPORATE UPDATE
DALLAS, TX, September 26, 2023 – Right on Brands, Inc. (OTC PINK: (RTOND), a fully reporting SEC filer and developer of a broad line of hemp-based and THC products, announces that the reverse is now effective. We are excited with the new corporate restructure, which will now enable the company to raise significant capital to
-
RemSleep Holdings Inc. Provides an Update on Funding and DeltaWave
Tampa, FL, September 25, 2023 – RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, announces a new investor agreement and DeltaWave submission update. RemSleep recently entered into a Purchase Agreement with Janbella Group, LLC which was the subject of
-
AURI Announces New CEO
DALLAS, TX, September 25, 2023 – Auri Inc. (OTC PINK: AURI) (“AURI”) (the “Company”) is proud to announce today our new CEO, Mr. Jim Amendola. Mr. Amendola has over 20 years of experience in manufacturing management experience. AURI will benefit immensely from having such a successful track record. Some of the companies Mr. Amendola has worked on
-
SKYX Platforms (SKYX) Increases Patent Count With Five Additional Issued in US and International
September 22, 2023 Today SKYX Platforms (SKYX) has announced the issuance of five new utility patents in the U.S. and international markets including Canada, Mexico and Hong Kong for its related smart plug-and-play products including a ceiling fan with a heater and recessed light. The company now has 77 issued and pending patents, globally. Recent Announcements Recently,
-
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The